Paper Details 
Original Abstract of the Article :
Epidermolysis bullosa (EB) is a group of genetic disorders that lead to blister formation at variable depths in skin and mucosa. Vesicles may arise spontaneously or be caused by friction or trauma. Oral tissue fragility and blistering is common in all EB types. The majority of patients with mild for...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1902/jop.2001.72.5.691

データ提供:米国国立医学図書館(NLM)

Sucralfate: A Potential Solution for Oral Management in Epidermolysis Bullosa

The field of dermatology is a vast and complex desert, where researchers strive to understand and treat the diverse skin conditions that affect millions of people. This study focuses on epidermolysis bullosa (EB), a group of genetic disorders characterized by severe skin fragility and blistering. The authors investigate the potential of sucralfate, a medication typically used to treat stomach ulcers, as a therapeutic agent for managing oral complications in patients with EB.

Sucralfate for Reducing Pain and Blistering in Patients with Epidermolysis Bullosa

This study provides encouraging evidence for the potential of sucralfate in reducing pain and the number of blisters in patients with EB. The findings suggest that sucralfate suspension may improve oral hygiene and reduce the incidence of caries in patients with EB, particularly those with severe mucosal involvement. This research offers a potential avenue for improving the oral health and quality of life for individuals living with EB.

Oral Care for Patients with Epidermolysis Bullosa

This study highlights the importance of tailored oral management strategies for patients with EB. The findings suggest that sucralfate may play a valuable role in reducing pain, preventing blisters, and maintaining oral hygiene in these patients. This research emphasizes the need for specialized care and support for individuals with EB, ensuring their oral health and overall well-being.

Dr. Camel's Conclusion

This research reveals a potential oasis of relief in the desert of dermatological challenges. The findings suggest that sucralfate may offer a valuable tool for managing oral complications in patients with epidermolysis bullosa, improving their quality of life and promoting oral health. As we continue to explore the desert of dermatological research, we are uncovering new possibilities for treating and managing skin conditions, seeking to alleviate suffering and improve the lives of those affected.

Date :
  1. Date Completed 2001-10-25
  2. Date Revised 2022-03-18
Further Info :

Pubmed ID

11394407

DOI: Digital Object Identifier

10.1902/jop.2001.72.5.691

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.